EP1451305A4 - Epitope synchronization in antigen presenting cells - Google Patents

Epitope synchronization in antigen presenting cells

Info

Publication number
EP1451305A4
EP1451305A4 EP02804113A EP02804113A EP1451305A4 EP 1451305 A4 EP1451305 A4 EP 1451305A4 EP 02804113 A EP02804113 A EP 02804113A EP 02804113 A EP02804113 A EP 02804113A EP 1451305 A4 EP1451305 A4 EP 1451305A4
Authority
EP
European Patent Office
Prior art keywords
presenting cells
antigen presenting
epitope synchronization
epitope
synchronization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02804113A
Other languages
German (de)
French (fr)
Other versions
EP1451305A2 (en
Inventor
John J L Simard
David C Diamond
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mannkind Corp
Original Assignee
Mannkind Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/026,066 external-priority patent/US20030215425A1/en
Application filed by Mannkind Corp filed Critical Mannkind Corp
Publication of EP1451305A2 publication Critical patent/EP1451305A2/en
Publication of EP1451305A4 publication Critical patent/EP1451305A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001189—PRAME
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001164—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001191—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001194—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001195—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
EP02804113A 2001-11-07 2002-11-05 Epitope synchronization in antigen presenting cells Withdrawn EP1451305A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5905 1993-01-15
US590501A 2001-11-07 2001-11-07
US10/026,066 US20030215425A1 (en) 2001-12-07 2001-12-07 Epitope synchronization in antigen presenting cells
US26066 2001-12-07
PCT/US2002/035582 WO2003057823A2 (en) 2001-11-07 2002-11-05 Epitope synchronization in antigen presenting cells

Publications (2)

Publication Number Publication Date
EP1451305A2 EP1451305A2 (en) 2004-09-01
EP1451305A4 true EP1451305A4 (en) 2005-10-05

Family

ID=26674912

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02804113A Withdrawn EP1451305A4 (en) 2001-11-07 2002-11-05 Epitope synchronization in antigen presenting cells

Country Status (4)

Country Link
EP (1) EP1451305A4 (en)
JP (2) JP2005514029A (en)
AU (1) AU2002365187A1 (en)
WO (1) WO2003057823A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006083792A2 (en) * 2005-01-31 2006-08-10 Vaxinnate Corporation Novel polypeptide ligands for toll-like receptor 2 (tlr2)
ES2579762T3 (en) 2006-03-01 2016-08-16 Janssen Pharmaceutica N.V. Cancer treatment by combining lympho - reducing agent with CLTs and cytokines
AR060424A1 (en) * 2007-04-11 2008-06-18 Consejo Nac Invest Cient Tec CELLULAR LINES, COMPOSITIONS FOR THE TREATMENT OF MELANOMS THAT UNDERSTAND PROCEDURES TO PREPARE COMPOSITIONS AND TREATMENT METHODS
JP6008461B2 (en) * 2007-07-27 2016-10-19 イマティクス バイオテクノロジーズ ゲーエムベーハー Novel immunotherapy for neuronal brain tumors
GB201408255D0 (en) * 2014-05-09 2014-06-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
CN109071605A (en) * 2016-04-06 2018-12-21 伊玛提克斯生物技术有限公司 New type of peptides and peptide combinations for AML and other cancer immunotherapies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683199A (en) * 1983-01-31 1987-07-28 Sloan-Kettering Institute For Cancer Research Interleukin-2 dependent cytotoxic T-cell clones
EP1117679B9 (en) * 1998-10-02 2010-07-07 Ludwig Institute For Cancer Research Tumor antigens and ctl clones isolated by a novel procedure

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
D'AMARO J ET AL: "A computer program for predicting possible cytotoxic T lymphocyte epitopes based on HLA class I peptide-binding motifs.", HUMAN IMMUNOLOGY. MAY 1995, vol. 43, no. 1, May 1995 (1995-05-01), pages 13 - 18, XP000603786, ISSN: 0198-8859 *
GACZYNSKA M ET AL: "Gamma-interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes.", NATURE. 16 SEP 1993, vol. 365, no. 6443, 16 September 1993 (1993-09-16), pages 264 - 267, XP002339971, ISSN: 0028-0836 *
GACZYNSKA M. ET AL.: "Corrections: Gamma-interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes.", NATURE, vol. 374, 16 March 1995 (1995-03-16), pages 290 *
KESSLER J H ET AL: "Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis.", THE JOURNAL OF EXPERIMENTAL MEDICINE. 1 JAN 2001, vol. 193, no. 1, 1 January 2001 (2001-01-01), pages 73 - 88, XP002339970, ISSN: 0022-1007 *
MOREL S ET AL: "Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells.", IMMUNITY. JAN 2000, vol. 12, no. 1, January 2000 (2000-01-01), pages 107 - 117, XP002339968, ISSN: 1074-7613 *
PAMER E ET AL: "Mechanisms of MHC class I--restricted antigen processing.", ANNUAL REVIEW OF IMMUNOLOGY. 1998, vol. 16, 1998, pages 323 - 358, XP002339969, ISSN: 0732-0582 *
ROCK K L ET AL: "DEGRADATION OF CELL PROTEINS AND THE GENERATION OF MHC CLASS I-PRESENTED PEPTIDES", ANNUAL REVIEW OF IMMUNOLOGY, ANNUAL REVIEWS INC, US, vol. 17, 1999, pages 739 - 779, XP000925560, ISSN: 0732-0582 *
VAN DEN EYNDE B J ET AL: "Differential processing of class-I-restricted epitopes by the standard proteasome and the immunoproteasome", CURRENT OPINION IN IMMUNOLOGY, CURRENT BIOLOGY LTD, vol. 13, no. 2, 1 April 2001 (2001-04-01), pages 147 - 153, XP004257777, ISSN: 0952-7915 *
WANG E ET AL: "T-cell-directed cancer vaccines: the melanoma model.", EXPERT OPINION ON BIOLOGICAL THERAPY. MAR 2001, vol. 1, no. 2, March 2001 (2001-03-01), pages 277 - 290, XP009052140, ISSN: 1471-2598 *

Also Published As

Publication number Publication date
WO2003057823A3 (en) 2004-03-25
EP1451305A2 (en) 2004-09-01
JP2005514029A (en) 2005-05-19
JP2009279006A (en) 2009-12-03
AU2002365187A1 (en) 2003-07-24
WO2003057823A2 (en) 2003-07-17
AU2002365187A8 (en) 2003-07-24

Similar Documents

Publication Publication Date Title
HUS2000035I1 (en) Cells producing antibody compositions
IL176006A0 (en) Immunogenic peptide carrier conjugates and methods for producing the same
AU2002323236A1 (en) In situ immunization
EP1572941A4 (en) Novel flavivirus antigens
HK1082520A1 (en) T cell vaccine and the method for preparing the same
EP1257565A4 (en) Mucin-1 derived antigens and their use in immunotherapy
IL164281A0 (en) Epitope constructs comprising antigen presenting cell targeting mechanisms
GB0206461D0 (en) Improvements in vaccination
AU2003207459A8 (en) Cancer-associated epitope
GB0126378D0 (en) Antigen
EP1390387A4 (en) Cancer-testis antigens
EP1399478A4 (en) Cancer-testis antigens
EP1558628A4 (en) Antigenic peptides
EP1165773A4 (en) Advanced antigen presentation platform
AU2003294220A8 (en) Ii-key/antigenic epitope hybrid peptide vaccines
AU2002365187A8 (en) Epitope synchronization in antigen presenting cells
EP1597356A4 (en) Cultured cd14+ antigen presenting cells
AU2002953238A0 (en) In vitro immunization
GB0215287D0 (en) 5T4 antigen expression
AU2003282241A8 (en) Antibodies for in vitro use
AU2001261534A1 (en) The meca-79 antigen and related methods
AU2002355054A1 (en) Human glioma antigen originating in testis
AU2002303093A1 (en) Mycobacterial vaccines
GB0126522D0 (en) Antigen
AU2002363391A1 (en) Antigen presenting vesicles

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040604

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: DIAMOND, DAVID, C.

Inventor name: SIMARD, JOHN, J., L.,SUITE # 7

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1071395

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20050824

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 07K 14/705 B

Ipc: 7A 61K 39/00 B

Ipc: 7C 12N 5/08 B

Ipc: 7C 12N 5/06 A

RIN1 Information on inventor provided before grant (corrected)

Inventor name: DIAMOND, DAVID, C.

Inventor name: SIMARD, JOHN, J., L.,SUITE 7

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20091203

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1071395

Country of ref document: HK